Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 5Phase 1/2 2Phase 3 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 5OTHER 4OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1

Conditions

Ovarian Neoplasms 1Non Hematologic Cancers 1Neoplasms 1Mesothelioma, Malignant 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × defactinib × Clear all
NCT02943317 2019-04-30

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

Verastem, Inc.

Phase 1 Terminated
98 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT01778803 2017-05-17

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer

Verastem, Inc.

Phase 1 Completed
22 enrolled
Gynecologic

Ovarian Neoplasms

NCT01943292 2017-03-09

Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies

Verastem, Inc.

Phase 1 Completed
9 enrolled 7 charts

Non Hematologic Cancers

NCT02372227 2017-01-30

A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

Verastem, Inc.

Phase 1 Terminated
21 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT00787033 2017-01-25

B0761001

Verastem, Inc.

Phase 1 Completed
46 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡